← Patent-cliff monitor small molecule HETLIOZ TASIMELTEON
Loss of exclusivity February 2041 latest FDA-listed patent expiry
Drug detail Brand name HETLIOZ Active ingredient TASIMELTEON Strength 20MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval January 2014 Marketing status RX
Listed patents Patent Expires Type 11759446 February 2041 use U-3003 11266622 August 2035 use U-3003 10179119 August 2035 use U-3003 10376487 July 2035 use U-3007 11566011 February 2035 substance, product 10071977 February 2035 substance, product 10829465 February 2035 substance, product 11760740 February 2035 substance, product 12049457 February 2035 substance, product 11786502 October 2034 use U-3739 11141400 October 2034 use U-3007 10610511 October 2034 use U-2615 9730910 May 2034 use U-3005 11918556 April 2033 use U-3343 11826339 January 2033 use U-3343 11285129 January 2033 use U-3343 9549913 January 2033 use U-1486 12201604 January 2033 use U-3865 9855241 January 2033 use U-2149 RE46604 January 2033 use U-2147 10149829 January 2033 use U-3006 9060995 January 2033 use U-1710 10449176 January 2033 use U-2149 10945988 January 2033 use U-2149 11633377 January 2033 use U-3003 10610510 January 2033 use U-2805 9539234 January 2033 use U-3004 10980770 January 2033 use U-3107 11850229 January 2033 use U-3343 11833130 January 2033 use U-3003 11918557 January 2033 use U-3865
Regulatory exclusivity Code Expires ODE-330 December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.